WuXi XDC: Strong Execution, Capacity Expansion and Robust Growth Outlook Support Maintained Buy Rating

WuXi XDC Cayman, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jill Wu from CMB International Securities maintained a Buy rating on the stock and has a HK$82.00 price target.

Jill Wu has given his Buy rating due to a combination of factors, most notably WuXi XDC’s strong operational performance and visibility of future growth. The company delivered rapid double‑digit revenue and profit expansion in 2025 and ended the year with a sharply higher order backlog and solid new contract wins, supporting management’s outlook for revenue to continue rising at an elevated pace while margins stay resilient.

At the same time, WuXi XDC is rapidly scaling its global manufacturing footprint through the BioDlink acquisition and large-scale capacity investments in China and overseas, which should enhance its competitive position in the fast-growing XDC CDMO market. Even after trimming earnings forecasts and lowering the DCF-derived target price, Jill Wu still expects robust revenue and profit growth over 2026–2028, underpinning a favorable risk‑reward profile that justifies maintaining a Buy recommendation.

Wu covers the Healthcare sector, focusing on stocks such as WuXi XDC Cayman, Inc., Pfizer, and Thermo Fisher. According to TipRanks, Wu has an average return of 30.8% and a 51.92% success rate on recommended stocks.